Abstract
Coronavirus Disease 2019 (COVID-19) infection, the pandemics, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has no known effective radical pharmacotherapy and just supportive approach at present. Amantadine is a drug used in Parkinson’s disease and other parkinsonisms; and is known to increase indirectly dopamine by antagonistic effects at the N-methyl-Daspartate (NMDA) receptor by increasing the release and blocking the reuptake of dopamine. Initially, amantadine was approved as an antiviral drug. We hypothesize that if amantadine is considered its antiviral, immunological and neurostimulant effects might be useful in the supportive treatment of SARSCoV- 2 cases, especially those who developed acute respiratory failure with decreased vigilance and are being monitored in the intensive care unit. Further phase III clinical trials are needed.
Keywords: Amantadine, pharmacology, neurology, SARS-CoV-2, drug repositioning, COVID-19.
Coronaviruses
Title:Amantadine Might be Used as a Drug for SARS-Cov-2 Treatment?
Volume: 2 Issue: 1
Author(s): Zeynep Gunes Ozunal and Sevki Sahin*
Affiliation:
- Neurology Department, Faculty of Medicine, Maltepe University, Istanbul,Turkey
Keywords: Amantadine, pharmacology, neurology, SARS-CoV-2, drug repositioning, COVID-19.
Abstract: Coronavirus Disease 2019 (COVID-19) infection, the pandemics, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has no known effective radical pharmacotherapy and just supportive approach at present. Amantadine is a drug used in Parkinson’s disease and other parkinsonisms; and is known to increase indirectly dopamine by antagonistic effects at the N-methyl-Daspartate (NMDA) receptor by increasing the release and blocking the reuptake of dopamine. Initially, amantadine was approved as an antiviral drug. We hypothesize that if amantadine is considered its antiviral, immunological and neurostimulant effects might be useful in the supportive treatment of SARSCoV- 2 cases, especially those who developed acute respiratory failure with decreased vigilance and are being monitored in the intensive care unit. Further phase III clinical trials are needed.
Export Options
About this article
Cite this article as:
Ozunal Gunes Zeynep and Sahin Sevki *, Amantadine Might be Used as a Drug for SARS-Cov-2 Treatment?, Coronaviruses 2021; 2 (1) . https://dx.doi.org/10.2174/2666796701999200713192912
DOI https://dx.doi.org/10.2174/2666796701999200713192912 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Orexins: Relation Between Sleeping, Eating, and Breathing
Current Respiratory Medicine Reviews In Silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology
Combinatorial Chemistry & High Throughput Screening Visuospatial Memory in Healthy Elderly, AD and MCI: A Review
Current Aging Science Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Skin Homing and Recruitment of Leukocytes in Allergic Contact Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery The Use of a Geographic Information System (GIS) to Study Spatial Distribution and Factors Associated with Stress Among Thai Adolescents
Adolescent Psychiatry Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Stress as a Pathophysiological Factor in Functional Somatic Syndromes
Current Psychiatry Reviews Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Diagnosis and Prognostic Evaluation for Xerostomia Using Dynamic MR Sialography
Current Medical Imaging An Update on GABAρ Receptors
Current Neuropharmacology PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Neurophysiology of Sleep and Wakefulness: Basic Science and Clinical Implications
Current Neuropharmacology Modeling and Informatics in Designing Anti-Diabetic Agents
Current Pharmaceutical Design Progress in Developing D3 Dopamine Receptor Ligands as Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders
Current Pharmaceutical Design Rescuing Mutant CFTR: A Multi-task Approach to a Better Outcome in Treating Cystic Fibrosis
Current Pharmaceutical Design Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Emerging Drugs for the Treatment of Cancer Pain: A Review of Patent Literature in 2014
Recent Patents on Anti-Cancer Drug Discovery